This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feldman, A. M. Search for Related Content PubMed PubMed Citation Articles by Feldman, A. M.

(Circulation. 2002;105:1876.)
© 2002 American Heart Association, Inc.

Editorial

Adenylyl Cyclase

A New Target for Heart Failure Therapeutics

Arthur M. Feldman, MD PhD

From the University of Pittsburgh Medical Center, Pittsburgh, Pa.

Correspondence to Arthur M. Feldman, MD, PhD, Harry S. Tack Professor of Medicine, University of Pittsburgh Medical Center, 200 Lothrop St, S-572 Scaife Hall, Pittsburgh, PA 15213. E-mail feldmanam@msx.upmc.edu

Key Words: Editorials • heart failure • signal transduction • adenylyl cyclase

In the early 1960s, Earl Sutherland and his colleagues performed a series of experiments that led to the understanding that the positive inotropic effects of ß-adrenergic agonists were mediated by the activation of the enzyme adenylyl cyclase (AC) and the subsequent production of cyclic adenosine monophosphate (cAMP).¹ By measuring tissue cAMP levels while simultaneously monitoring the mechanical properties of the heart, these investigators were able to show that cAMP levels increased with extraordinary speed, an increase that correlated directly with increased force of contraction. Subsequent studies demonstrated that AC activity is enhanced through a pathway beginning with ligand binding to ß₁-adrenergic receptors (ß₁ARs) and subsequent activation of stimulatory guanine nucleotide–binding signal transduction proteins (G_s). The resultant production of cAMP mediates improvements in both cardiac inotropy and lusitropy via stimulation of cAMP-dependent protein kinase A and the protein kinase A–dependent phosphorylation of key target proteins, including the L-type calcium channel, phospholamban, and troponin I. In the normal heart, activation of the ßAR–G protein–AC pathway effects enhanced contractility, which is paramount in facilitating the "flight or fight" response. However, in the failing human heart, profound alterations in multiple components of this ßAR–G protein–AC signal transduction cascade reduce cardiac reserve and contribute to decreased exercise response in patients with heart failure.² Paradoxically, long-term activation of the neurohormonal pathway accelerates the natural history of heart failure.

See p 1989

Thus, a therapeutic conundrum has arisen: How can one enhance myocardial contractility while at the same time protecting the heart from the . . . [Full Text of this Article]

This article has been cited by other articles:

				T. Tang, M. H. Gao, N. C. Lai, A. L. Firth, T. Takahashi, T. Guo, J. X.-J. Yuan, D. M. Roth, and H. K. Hammond Adenylyl Cyclase Type 6 Deletion Decreases Left Ventricular Function via Impaired Calcium Handling Circulation, January 1, 2008; 117(1): 61 - 69. [Abstract] [Full Text] [PDF]

				J. S. Swaney, H. H. Patel, U. Yokoyama, N. C. Lai, M. Spellman, P. A. Insel, and D. M. Roth Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3216 - H3220. [Abstract] [Full Text] [PDF]

				T. Matsumoto, K. Wakabayashi, T. Kobayashi, and K. Kamata Functional changes in adenylyl cyclases and associated decreases in relaxation responses in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2234 - H2243. [Abstract] [Full Text] [PDF]

				S. D. Carvalho-Bianco, B. W. Kim, J. X. Zhang, J. W. Harney, R. S. Ribeiro, B. Gereben, A. C. Bianco, U. Mende, and P. R. Larsen Chronic Cardiac-Specific Thyrotoxicosis Increases Myocardial {beta}-Adrenergic Responsiveness Mol. Endocrinol., July 1, 2004; 18(7): 1840 - 1849. [Abstract] [Full Text] [PDF]

				J. J. Saucerman, L. L. Brunton, A. P. Michailova, and A. D. McCulloch Modeling {beta}-Adrenergic Control of Cardiac Myocyte Contractility in Silico J. Biol. Chem., November 28, 2003; 278(48): 47997 - 48003. [Abstract] [Full Text] [PDF]

				A. M. El-Mowafy and M. Alkhalaf Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism Carcinogenesis, May 1, 2003; 24(5): 869 - 873. [Abstract] [Full Text] [PDF]

				R. S. Ostrom, X. Liu, B. P. Head, C. Gregorian, T. M. Seasholtz, and P. A. Insel Localization of Adenylyl Cyclase Isoforms and G Protein-Coupled Receptors in Vascular Smooth Muscle Cells: Expression in Caveolin-Rich and Noncaveolin Domains Mol. Pharmacol., November 1, 2002; 62(5): 983 - 992. [Abstract] [Full Text] [PDF]

				M. H. Gao, H. Bayat, D. M Roth, J. Yao Zhou, J. Drumm, J. Burhan, and H Kirk Hammond Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function Cardiovasc Res, November 1, 2002; 56(2): 197 - 204. [Abstract] [Full Text] [PDF]